201 related articles for article (PubMed ID: 34022222)
1. Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide.
Kamm DR; Pyles KD; Sharpe MC; Healy LN; Colca JR; McCommis KS
J Biol Chem; 2021; 296():100807. PubMed ID: 34022222
[TBL] [Abstract][Full Text] [Related]
2. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
Harrison SA; Alkhouri N; Davison BA; Sanyal A; Edwards C; Colca JR; Lee BH; Loomba R; Cusi K; Kolterman O; Cotter G; Dittrich HC
J Hepatol; 2020 Apr; 72(4):613-626. PubMed ID: 31697972
[TBL] [Abstract][Full Text] [Related]
3. MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis.
Colca JR; McDonald WG; Adams WJ
Expert Opin Investig Drugs; 2018 Jul; 27(7):631-636. PubMed ID: 29950116
[TBL] [Abstract][Full Text] [Related]
4. Novel thiazolidinedione analog reduces a negative impact on bone and mesenchymal stem cell properties in obese mice compared to classical thiazolidinediones.
Benova A; Ferencakova M; Bardova K; Funda J; Prochazka J; Spoutil F; Cajka T; Dzubanova M; Balcaen T; Kerckhofs G; Willekens W; van Lenthe GH; Alquicer G; Pecinova A; Mracek T; Horakova O; Rossmeisl M; Kopecky J; Tencerova M
Mol Metab; 2022 Nov; 65():101598. PubMed ID: 36103974
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice.
Liu Q; Cai BY; Zhu LX; Xin X; Wang X; An ZM; Li S; Hu YY; Feng Q
Life Sci; 2020 Nov; 261():118457. PubMed ID: 32961235
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial pyruvate carrier inhibition initiates metabolic crosstalk to stimulate branched chain amino acid catabolism.
Ferguson D; Eichler SJ; Yiew NKH; Colca JR; Cho K; Patti GJ; Shew TM; Lutkewitte AJ; Mukherjee S; McCommis KS; Niemi NM; Finck BN
Mol Metab; 2023 Apr; 70():101694. PubMed ID: 36801448
[TBL] [Abstract][Full Text] [Related]
7. Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats.
Larsen PJ; Wulff EM; Gotfredsen CF; Brand CL; Sturis J; Vrang N; Knudsen LB; Lykkegaard K
Diabetes Obes Metab; 2008 Apr; 10(4):301-11. PubMed ID: 18333889
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis.
Kojima M; Takahashi H; Kuwashiro T; Tanaka K; Mori H; Ozaki I; Kitajima Y; Matsuda Y; Ashida K; Eguchi Y; Anzai K
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32785012
[TBL] [Abstract][Full Text] [Related]
9. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
[TBL] [Abstract][Full Text] [Related]
10. [The protection of islet β-cells in db/db mice by combination pioglitazone and glucagon like peptide-1 treatment].
Song LL; Xiao JZ; Yang WY; Zhang M; Liu BB; Pan L
Zhonghua Nei Ke Za Zhi; 2011 Sep; 50(9):781-4. PubMed ID: 22176969
[TBL] [Abstract][Full Text] [Related]
11. Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy.
Martinez R; Al-Jobori H; Ali AM; Adams J; Abdul-Ghani M; Triplitt C; DeFronzo RA; Cersosimo E
Diabetes; 2018 Jun; 67(6):1182-1189. PubMed ID: 29602791
[TBL] [Abstract][Full Text] [Related]
12. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
13. Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis.
McCommis KS; Hodges WT; Brunt EM; Nalbantoglu I; McDonald WG; Holley C; Fujiwara H; Schaffer JE; Colca JR; Finck BN
Hepatology; 2017 May; 65(5):1543-1556. PubMed ID: 28027586
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
[TBL] [Abstract][Full Text] [Related]
15. Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis.
Choi YJ; Johnson JD; Lee JJ; Song J; Matthews M; Hellerstein MK; McWherter CA
Am J Physiol Gastrointest Liver Physiol; 2024 Feb; 326(2):G120-G132. PubMed ID: 38014444
[TBL] [Abstract][Full Text] [Related]
16. Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot study.
Yamamoto S; Hayashi T; Ohara M; Goto S; Sato J; Nagaike H; Fukase A; Sato N; Hiromura M; Tomoyasu M; Nakanishi N; Lee S; Osamura A; Yamamoto T; Fukui T; Hirano T
Diabetes Res Clin Pract; 2018 Jun; 140():339-346. PubMed ID: 29588170
[TBL] [Abstract][Full Text] [Related]
17. Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled study.
Elkind-Hirsch KE; Shaler D; Harris R
J Diabetes Complications; 2020 Apr; 34(4):107548. PubMed ID: 32046931
[TBL] [Abstract][Full Text] [Related]
18. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.
Somm E; Montandon SA; Loizides-Mangold U; Gaïa N; Lazarevic V; De Vito C; Perroud E; Bochaton-Piallat ML; Dibner C; Schrenzel J; Jornayvaz FR
Transl Res; 2021 Jan; 227():75-88. PubMed ID: 32711187
[TBL] [Abstract][Full Text] [Related]
19. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
[TBL] [Abstract][Full Text] [Related]
20. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.
Davison BA; Harrison SA; Cotter G; Alkhouri N; Sanyal A; Edwards C; Colca JR; Iwashita J; Koch GG; Dittrich HC
J Hepatol; 2020 Dec; 73(6):1322-1332. PubMed ID: 32610115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
